- Deferoxamine
- Deferoxamine mesylate
- 70519-79-83,4-Thiophenediamine,tetrahydro-, 1,1-dioxide, hydrochloride (1:2)
- 705-21-5Benzenesulfonylchloride, 3,5-dichloro-
- 70521-71-0b-Alanine,N-(2-hydroxyethyl)-N-(2-hydroxytetradecyl)-
- 70521-73-2b-Alanine,N-(2-hydroxyethyl)-N-(2-hydroxyoctadecyl)-
- 70521-74-3b-Alanine,N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-, monosodium salt (9CI)
- 70521-75-4b-Alanine, N-(2-hydroxyethyl)-N-(2-hydroxytetradecyl)-,monosodium salt (9CI)
- 70522-05-3Ajmalan-17-one,19,20-didehydro-11-methoxy-, (19E)- (9CI)
- 70523-22-7Boronic acid,B-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)-
- 70523-24-9Boronic acid,B-[2,4-bis(phenylmethoxy)-5-pyrimidinyl]-
- 705-24-8Pyrimidine,4,6-dichloro-2-(trifluoromethyl)-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Deferoxamine |
EINECS | 200-738-5 |
| CAS No. | 70-51-9 | Density | 1.212g/cm3 |
| PSA | 205.84000 | LogP | 2.40420 |
| Solubility | N/A | Melting Point |
139°C |
| Formula | C25H48 N6 O8 | Boiling Point | 627.9°C (rough estimate) |
| Molecular Weight | 560.692 | Flash Point | N/A |
| Transport Information | N/A | Appearance | N/A |
| Safety | Poison by intravenous route. Moderately toxic by ingestion, intraperitoneal and subcutaneous routes. Human systemic effects: changes in hearing acuity, eye hemorrhage, optic nerve neuropathy, thrombocytopenia, visual field changes. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx. | Risk Codes | N/A |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
Butanediamide,N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-(9CI); Propionohydroxamic acid,N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-(8CI); 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25pentaazatriacontane-2,10,13,21,24-pentaone; Deferoxamin; Deferoxamine;Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Deferrioxamine B;Desferan; Desferex; Desferin; Desferioxamine B; Desferrin; Desferrioxamine;Desferrioxamine B;N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamicacid; NSC 527604 |
Article Data | 10 |
Deferoxamine Synthetic route
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| With palladium 10% on activated carbon; hydrogen; acetic acid In methanol at 25℃; under 760.051 Torr; for 0.333333h; | 50% |
- 402913-84-2
1-Carbobenzoxyamino-6,17-dihydroxy-7,10,18,21-tetraoxy-27-(N-acetyl-hydroxyamino)-6,11,17,22-tetraaza-hepteikosan
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| With hydrogenchloride; hydrogen; palladium on activated charcoal In methanol |
- 112139-65-8
N'-<5-<<4-<<5-pentyl>amino>-1,4-dioxobutyl>(phenylmethoxy)amino>pentyl>-N-(4-cyanobutyl)-N-(phenylmethoxy)butanediamide
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| With hydrogenchloride; hydrogen; palladium on activated charcoal In methanol |
- 129245-21-2
N-(5-aminopentyl)-N-(tert-butoxycarbonyl)-O-benzylhydroxylamine
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 7 steps 1: 99 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 2: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C 3: 96 percent / pyridine 4: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 5: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 6: 91 percent / pyridine / 12 h 7: H2, HCl / 10percent Pd/C / methanol View Scheme |
- 129245-24-5
5,16-bis(benzyloxy)-20-cyano-4,12,15-trioxo-5,11,16-triazaeicosanoic acid
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 4 steps 1: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 2: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 3: 91 percent / pyridine / 12 h 4: H2, HCl / 10percent Pd/C / methanol View Scheme |
- 130946-41-7
27--6,17-bis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22-tetraazaheptacosanenitrile
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1: 91 percent / pyridine / 12 h 2: H2, HCl / 10percent Pd/C / methanol View Scheme |
- 130946-40-6
27--6,17-bis(benzyloxy)-7,10,18,21-tetraoxo-6,11,17,22-tetraazaheptacosanenitrile
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 2: 91 percent / pyridine / 12 h 3: H2, HCl / 10percent Pd/C / methanol View Scheme |
- 112139-60-3
N-(4-Cyanobutyl)-N-(benzyloxy)succinamic Acid
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 7 steps 1: 99 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 2: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C 3: 96 percent / pyridine 4: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 5: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 6: 91 percent / pyridine / 12 h 7: H2, HCl / 10percent Pd/C / methanol View Scheme |
- 129245-23-4
N-(4-cyanobutyl)-3-<<5-<(benzyloxy)amino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 5 steps 1: 96 percent / pyridine 2: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 3: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 4: 91 percent / pyridine / 12 h 5: H2, HCl / 10percent Pd/C / methanol View Scheme |
- 129245-22-3
N-(4-cyanobutyl)-3-<<5-<(benzyloxy)-tert-butoxy-carbonylamino>pentyl>carbamoyl>-O-benzylpropionohydroxamic acid
- 70-51-9
deferoxamine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 6 steps 1: 87 percent / trifluoroacetic acid (TFA) / CH2Cl2 / 0.75 h / 0 - 20 °C 2: 96 percent / pyridine 3: 95 percent / diphenyl phosphorazidate, triethylamine / dimethylformamide / 17 h / 0 - 20 °C 4: 100 percent / trifluoroacetic acid (TFA) / CH2Cl2 5: 91 percent / pyridine / 12 h 6: H2, HCl / 10percent Pd/C / methanol View Scheme |
Deferoxamine Chemical Properties
Molecular Formula: C25H48N6O8
Molar mass: 560.684 g/mol
EINECS: 200-738-5
Density: 1.212 g/cm3
Index of Refraction: 1.537
Structure of Deferoxamine (CAS NO.70-51-9):
Deferoxamine Uses
Deferoxamine (CAS NO.70-51-9) is used to treat acute iron poisoning, especially in small children and is also frequently used to treat hemochromatosis, a disease of iron accumulation that can be either genetic or acquired. Another, it has also been used in the treatment of a patient with aceruloplasminemia.
Deferoxamine Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| child | TDLo | multiple routes | 440mg/kg/6D-I (440mg/kg) | SENSE ORGANS AND SPECIAL SENSES: "RETINAL CHANGES (PIGMENTARY DEPOSITIONS, RETINITIS, OTHER): EYE" | Archives of Disease in Childhood. Vol. 63, Pg. 250, 1988. |
| child | TDLo | subcutaneous | 12gm/kg/17W-I (12000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR | New England Journal of Medicine. Vol. 314, Pg. 869, 1986. |
| human | TDLo | subcutaneous | 37gm/kg/2Y-I (37000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE | New England Journal of Medicine. Vol. 314, Pg. 869, 1986. |
| man | TDLo | intravenous | 86mg/kg/1H-C (86mg/kg) | BLOOD: THROMBOCYTOPENIA | American Journal of Kidney Diseases. Vol. 6, Pg. 254, 1985. |
| mouse | LD50 | intraperitoneal | 1680mg/kg (1680mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 99, 1970. | |
| mouse | LD50 | intravenous | 250mg/kg (250mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA | United States Patent Document. Vol. #4863964, |
| mouse | LD50 | oral | 1340mg/kg (1340mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 17, Pg. 748, 1967. | |
| mouse | LD50 | subcutaneous | 1450mg/kg (1450mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975. | |
| rat | LD50 | intravenous | 329mg/kg (329mg/kg) | Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971. | |
| rat | LD50 | subcutaneous | 12240mg/kg (12240mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975. | |
| women | TDLo | intravenous | 40mg/kg (40mg/kg) | SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SENSE ORGANS AND SPECIAL SENSES: HEMORRHAGE: EYE | Nephron. Vol. 46, Pg. 211, 1987. |
Deferoxamine Safety Profile
Poison by intravenous route. Moderately toxic by ingestion, intraperitoneal and subcutaneous routes. Human systemic effects: changes in hearing acuity, eye hemorrhage, optic nerve neuropathy, thrombocytopenia, visual field changes. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Deferoxamine Specification
Deferoxamine ,its cas register number is 70-51-9. It also can be called Desferrioxamine B ; Desferoxamine B ; DFO-B ; DFOA ; DFB or Desferal . It acts by binding free iron in the bloodstream and enhancing its elimination in the urine. Deferoxamine (CAS NO.70-51-9) may modulate expression and release of inflammatory mediators by specific cell types. A recent study shows that it speeds healing of nerve damage. Its administration after acute intoxication may color the urine a pinkish red, a phenomenon termed "vin rose urine".
What can I do for you?
Get Best Price
